6,725 Shares in Amgen Inc. $AMGN Acquired by Atlas Capital Advisors Inc.

Atlas Capital Advisors Inc. purchased a new position in Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 6,725 shares of the medical research company’s stock, valued at approximately $2,201,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Anfield Capital Management LLC increased its holdings in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC increased its holdings in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the period. Board of the Pension Protection Fund acquired a new position in Amgen in the 4th quarter worth approximately $26,000. Manning & Napier Advisors LLC increased its holdings in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new position in Amgen in the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.85% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research reports. UBS Group increased their price target on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Barclays initiated coverage on shares of Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. Guggenheim dropped their price objective on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research note on Monday, May 4th. Finally, Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $354.12.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $355.20 on Friday. The stock has a market capitalization of $191.70 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 3.56 and a beta of 0.42. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29. The firm’s 50 day simple moving average is $340.97 and its 200-day simple moving average is $345.72. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts expect that Amgen Inc. will post 22.38 EPS for the current year.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.